Condition
Steroid Refractory Acute Graft Versus Host Disease
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Terminated1
Unknown1
Clinical Trials (2)
Showing 2 of 2 trials
NCT03172455Unknown
Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)
NCT02524847Phase 3TerminatedPrimary
Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease
Showing all 2 trials